Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1986 1
1987 2
1988 6
1989 6
1990 1
1991 7
1992 2
1993 4
1996 2
1997 1
1999 2
2000 2
2002 6
2003 2
2004 2
2005 7
2006 10
2007 8
2008 11
2009 7
2010 13
2011 10
2012 14
2013 13
2014 16
2015 13
2016 14
2017 19
2018 11
2019 16
2020 18
2021 18
2022 13
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Results by year

Filters applied: . Clear all
Page 1
HER3 in cancer: from the bench to the bedside.
Gandullo-Sánchez L, Ocaña A, Pandiella A. Gandullo-Sánchez L, et al. Among authors: pandiella a. J Exp Clin Cancer Res. 2022 Oct 21;41(1):310. doi: 10.1186/s13046-022-02515-x. J Exp Clin Cancer Res. 2022. PMID: 36271429 Free PMC article. Review.
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
Duro-Sánchez S, Nadal-Serrano M, Lalinde-Gutiérrez M, Arenas EJ, Bernadó Morales C, Morancho B, Escorihuela M, Pérez-Ramos S, Escrivá-de-Romaní S, Gandullo-Sánchez L, Pandiella A, Esteve-Codina A, Rodilla V, Dijcks FA, Dokter WHA, Cortés J, Saura C, Arribas J. Duro-Sánchez S, et al. Among authors: pandiella a. Cancer Res. 2022 Dec 16;82(24):4670-4679. doi: 10.1158/0008-5472.CAN-22-0787. Cancer Res. 2022. PMID: 36222720 Free PMC article.
Resistance to Antibody-Drug Conjugates.
García-Alonso S, Ocaña A, Pandiella A. García-Alonso S, et al. Among authors: pandiella a. Cancer Res. 2018 May 1;78(9):2159-2165. doi: 10.1158/0008-5472.CAN-17-3671. Epub 2018 Apr 13. Cancer Res. 2018. PMID: 29653942 Review.
Refining Early Antitumoral Drug Development.
Ocaña A, García-Alonso S, Amir E, Pandiella A. Ocaña A, et al. Among authors: pandiella a. Trends Pharmacol Sci. 2018 Nov;39(11):922-925. doi: 10.1016/j.tips.2018.09.003. Epub 2018 Sep 29. Trends Pharmacol Sci. 2018. PMID: 30279003 Review.
ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology.
Arconada-Luque E, Jiménez-Suarez J, Pascual-Serra R, Nam-Cha SH, Moline T, Cimas FJ, Fliquete G, Ortega-Muelas M, Roche O, Fernández-Aroca DM, Muñoz Velasco R, García-Flores N, Garnés-García C, Sánchez-Fdez A, Matilla-Almazán S, Sánchez-Arévalo Lobo VJ, Hernández-Losa J, Belandia B, Pandiella A, Esparís-Ogando A, Ramón Y Cajal S, Del Peso L, Sánchez-Prieto R, Ruiz-Hidalgo MJ. Arconada-Luque E, et al. Among authors: pandiella a. Cancers (Basel). 2022 Jul 19;14(14):3509. doi: 10.3390/cancers14143509. Cancers (Basel). 2022. PMID: 35884568 Free PMC article.
Neuregulins and cancer.
Montero JC, Rodríguez-Barrueco R, Ocaña A, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A. Montero JC, et al. Among authors: pandiella a. Clin Cancer Res. 2008 Jun 1;14(11):3237-41. doi: 10.1158/1078-0432.CCR-07-5133. Clin Cancer Res. 2008. PMID: 18519747 Review.
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.
Noblejas-López MDM, Gandullo-Sánchez L, Galán-Moya EM, López-Rosa R, Tébar-García D, Nieto-Jiménez C, Gómez-Juárez M, Burgos M, Pandiella A, Ocaña A. Noblejas-López MDM, et al. Among authors: pandiella a. Int J Mol Sci. 2022 May 13;23(10):5476. doi: 10.3390/ijms23105476. Int J Mol Sci. 2022. PMID: 35628286 Free PMC article.
Transforming growth factor-alpha.
Pandiella A, Massague J. Pandiella A, et al. Biochem Soc Trans. 1991 Apr;19(2):259-62. doi: 10.1042/bst0190259. Biochem Soc Trans. 1991. PMID: 1889609 Review. No abstract available.
257 results